UNC Lineberger Comprehensive Cancer Center member Jim Evans, MD, PhD, Bryson Distinguished Professor of Genetics and Medicine and director of clinical cancer genetics, has co-authored a commentary on proposed US Food and Drug Administration (FDA) regulation of genetic testing in the Journal of the American Medical Association (JAMA).
UNC Lineberger researchers and colleagues at The University of Texas MD Anderson Cancer Center have developed a new approach to block the KRAS oncogene, one of the most frequently mutated genes in human cancer. The approach, led by Chad Pecot, MD, an assistant professor of medicine at UNC, offers another route to attack KRAS, which has proven to be an elusive and frustrating target for drug developers.
UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic “drivers” of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy. The study, published online August 24 in Nature Genetics, was authored by Michael Gatza, PhD, lead author and post-doctoral research associate; Grace Silva, graduate student; Joel Parker, PhD, director of bioinformatics, UNC Lineberger; Cheng Fan, research associate; and senior author Chuck Perou, PhD, professor of genetics and pathology.
Faculty members at the University of North Carolina School of Dentistry, The Scripps Research Institute (TSRI) and other institutions have discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that target the cancer’s underlying genetic causes.
Personalized medicine holds great promise for delivering targeted treatments to patients based on their unique genetic characteristics. Through a $3.5 million, five-year grant from the National Cancer Institute (NCI), UNC Lineberger Comprehensive Cancer Center will provide high-throughput RNA and DNA sequencing and regulatory assistance to partner institutions in the NCI’s new National Clinical Trials Network (NCTN).
James P. Evans, MD, PhD, Bryson Distinguished Professor of Genetics and Medicine, was quoted on National Public Radio’s All Things Considered regarding the Food and Drug Administration’s warning letter sent to the company 23andMe demanding that its saliva test be taken off the market.